Strain Information | |
---|---|
Image | |
BRC No. | RBRC11168 |
Type | Targeted Mutation![]() |
Species | Mus musculus |
Strain name | C57BL/6-Itgae<tm1.1Ksat> |
Former Common name | Cd103<-/-> mice |
H-2 Haplotype | |
ES Cell line | |
Background strain | |
Appearance | |
Strain development | Deposited by Katsuaki Sato, RIKEN in 2020. Mice were generated using JN/2 ES cells derived from C57BL/6. C57BL/6 genetic background. |
Strain description | Itgae mutant mice. STOP cassette was kncoked-in at the exon 1 of the Cd103 (Itgae). |
Colony maintenance | |
References | Pivotal role of CD103 in the development of psoriasiform dermatitis. Fukui T, Fukaya T, Uto T, Takagi H, Nasu J, Miyanaga N, Nishikawa Y, Koseki H, Choijookhuu N, Hishikawa Y, Yamashita Y, Sato K Sci. Rep., 10(1):8371 (2020). 32433498 |
Health Report | |
---|---|
Examination Date / Room / Rack |
Gene | |||||||
---|---|---|---|---|---|---|---|
Gene Symbol | Gene Name | Chr. | Allele Symbol | Allele Name | Common Names | Promoter | Diseases Related to This Gene |
EGFP | Enhanced Green Fluorescent Protein (Aequorea victoria) | 11 | EGFP | ||||
Frt | yeast FRT (flippase recombination target) site | 11 | Frt | ||||
HBEGF | heparin-binding EGF-like growth factor (human) | 11 | HBEGF | ||||
IRES2 | internal ribosomal entry site (EMCV) | 11 | IRES2 | ||||
Itgae MGI:1298377 | integrin alpha E, epithelial-associated | 11 | Itgae<tm1.1Ksat> | targeted mutation 1.1, Katsuaki Sato | |||
loxP | phage P1 loxP | 11 | loxP | ||||
loxP | phage P1 loxP | 11 | loxP | ||||
SV40 polyA | 11 |
Phenotype | |
---|---|
Annotation by Mammalian phenotyhpe ontology | |
Detailed phenotype data |
Ordering Information | |
---|---|
Donor DNA | Saccharomyces cerevisiae FRT site, human HB-EGF cDNA, EMCV IRES2, Aequorea Victoria EGFP cDNA, Simian virus 40 polyA, Saccharomyces cerevisiae DEAD-box ATP-dependent RNA helicase DED1, Phage P1 loxP sites, mouse Itgae genomic DNA |
Research application | Cre/loxP system FLP/frt system Fluorescent Proteins/lacZ System |
Specific Term and Conditions | In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Sci Rep. May 20;10(1):8371 (2020). doi: 10.1038/s41598-020-65355-9.In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Sci. Rep. 10:8371, 2020. Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must obtain approval from the DEVELOPER (Dr. Katsuaki Sato) using the Approval Form. The Recipient acknowledges that RIKEN (and/or its original provider) reserves title to the Material. The Recipient will not transfer the Material to any scientists. The Recipient will not publish or present Research result without obtaining prior permission fromthe DEVELOPER (Dr. Katsuaki Sato). The Recipient will send Dr. Katsuaki Sato any abstract of submission, oral or written presentation, and/or copy of draft of paper or research article which is resulted from the Research at least 30 days prior to the submission. The RECIPIENT agrees to use this BIOLOGICAL RESOURCE as a collaboration with the DEVELOPER (Dr. Katsuaki Sato). |
Depositor | Haruhiko Koseki (RIKEN) |
Strain Status | ![]() ![]() |
Strain Availability | Recovered litters from cryopreserved embryos (2 to 4 months) Cryopreserved sperm (within 1 month) |
Additional Info. | Necessary documents for ordering:
Genotyping protocol -PCR- |
BRC mice in Publications |
---|
No Data |